Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database

Wen Shyong Liou, Shu Ching Hsieh, Wai Yuan Chang, Grace Hui Min Wu, Hsu Shan Huang, Chuanfang Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: This study aimed to explore whether physicians prescribe more brand-name oral hypoglycemic agents (OHA) for diabetic patients with medical training background (MP) than for general patients (GP). Research design and methods: A longitudinal analysis of 1000000 National Health Insurance cohorts of 1998-2008 was conducted. Univariate and multivariate models were performed to assess the associations of the outcome (the ratio of brand-name/generic odds in the MP group to that in the GP group) and the covariates, including patient medical training background, characteristics of patient, prescriber, and medical settings, and market competition. A generalized estimating equation method was used to control the dependency of longitudinal data. Results: A total of 46850 diabetic patients were prescribed with 2703149 OHA prescriptions during the study period. Compared with GP, MP had 1.37 times greater odds of being prescribed with brand-name instead of generic OHA, among whom pharmacists and physicians had the highest odds ratios of 2.78 (95%CI, 1.05-7.36) and 1.68 (95%CI, 0.99-2.85), respectively. Patients' diabetes severity, prescribers' level of experience, medical settings that were publicly owned, had a higher accreditation level, and were located in a higher urbanized area, lower market competition, and earlier dates of prescription were positively associated with brand-name prescription. Among all medical sub-specialties, cardiologists were more likely to prescribe brand-name OHA. Conclusions: This study is the first to demonstrate how a patients' medical training background, in addition to the characteristics of patients, prescribers, and medical settings, and market competition might influence physicians' prescribing choice of brand-name or generic OHA.

Original languageEnglish
Pages (from-to)752-759
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume22
Issue number7
DOIs
Publication statusPublished - Jul 2013
Externally publishedYes

Fingerprint

Health Insurance Reimbursement
National Health Programs
Names
Databases
Health
Hypoglycemic Agents
Prescriptions
Physicians
Accreditation
Pharmacists
Research Design
Odds Ratio
Medicine

Keywords

  • Brand name or generic
  • Database analysis
  • Pharmacoepidemiology
  • Prescribing behavior

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Cite this

Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database. / Liou, Wen Shyong; Hsieh, Shu Ching; Chang, Wai Yuan; Wu, Grace Hui Min; Huang, Hsu Shan; Lee, Chuanfang.

In: Pharmacoepidemiology and Drug Safety, Vol. 22, No. 7, 07.2013, p. 752-759.

Research output: Contribution to journalArticle

@article{1b1dce4da0fd48d49252726b9d5ea2b5,
title = "Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database",
abstract = "Objective: This study aimed to explore whether physicians prescribe more brand-name oral hypoglycemic agents (OHA) for diabetic patients with medical training background (MP) than for general patients (GP). Research design and methods: A longitudinal analysis of 1000000 National Health Insurance cohorts of 1998-2008 was conducted. Univariate and multivariate models were performed to assess the associations of the outcome (the ratio of brand-name/generic odds in the MP group to that in the GP group) and the covariates, including patient medical training background, characteristics of patient, prescriber, and medical settings, and market competition. A generalized estimating equation method was used to control the dependency of longitudinal data. Results: A total of 46850 diabetic patients were prescribed with 2703149 OHA prescriptions during the study period. Compared with GP, MP had 1.37 times greater odds of being prescribed with brand-name instead of generic OHA, among whom pharmacists and physicians had the highest odds ratios of 2.78 (95{\%}CI, 1.05-7.36) and 1.68 (95{\%}CI, 0.99-2.85), respectively. Patients' diabetes severity, prescribers' level of experience, medical settings that were publicly owned, had a higher accreditation level, and were located in a higher urbanized area, lower market competition, and earlier dates of prescription were positively associated with brand-name prescription. Among all medical sub-specialties, cardiologists were more likely to prescribe brand-name OHA. Conclusions: This study is the first to demonstrate how a patients' medical training background, in addition to the characteristics of patients, prescribers, and medical settings, and market competition might influence physicians' prescribing choice of brand-name or generic OHA.",
keywords = "Brand name or generic, Database analysis, Pharmacoepidemiology, Prescribing behavior",
author = "Liou, {Wen Shyong} and Hsieh, {Shu Ching} and Chang, {Wai Yuan} and Wu, {Grace Hui Min} and Huang, {Hsu Shan} and Chuanfang Lee",
year = "2013",
month = "7",
doi = "10.1002/pds.3445",
language = "English",
volume = "22",
pages = "752--759",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database

AU - Liou, Wen Shyong

AU - Hsieh, Shu Ching

AU - Chang, Wai Yuan

AU - Wu, Grace Hui Min

AU - Huang, Hsu Shan

AU - Lee, Chuanfang

PY - 2013/7

Y1 - 2013/7

N2 - Objective: This study aimed to explore whether physicians prescribe more brand-name oral hypoglycemic agents (OHA) for diabetic patients with medical training background (MP) than for general patients (GP). Research design and methods: A longitudinal analysis of 1000000 National Health Insurance cohorts of 1998-2008 was conducted. Univariate and multivariate models were performed to assess the associations of the outcome (the ratio of brand-name/generic odds in the MP group to that in the GP group) and the covariates, including patient medical training background, characteristics of patient, prescriber, and medical settings, and market competition. A generalized estimating equation method was used to control the dependency of longitudinal data. Results: A total of 46850 diabetic patients were prescribed with 2703149 OHA prescriptions during the study period. Compared with GP, MP had 1.37 times greater odds of being prescribed with brand-name instead of generic OHA, among whom pharmacists and physicians had the highest odds ratios of 2.78 (95%CI, 1.05-7.36) and 1.68 (95%CI, 0.99-2.85), respectively. Patients' diabetes severity, prescribers' level of experience, medical settings that were publicly owned, had a higher accreditation level, and were located in a higher urbanized area, lower market competition, and earlier dates of prescription were positively associated with brand-name prescription. Among all medical sub-specialties, cardiologists were more likely to prescribe brand-name OHA. Conclusions: This study is the first to demonstrate how a patients' medical training background, in addition to the characteristics of patients, prescribers, and medical settings, and market competition might influence physicians' prescribing choice of brand-name or generic OHA.

AB - Objective: This study aimed to explore whether physicians prescribe more brand-name oral hypoglycemic agents (OHA) for diabetic patients with medical training background (MP) than for general patients (GP). Research design and methods: A longitudinal analysis of 1000000 National Health Insurance cohorts of 1998-2008 was conducted. Univariate and multivariate models were performed to assess the associations of the outcome (the ratio of brand-name/generic odds in the MP group to that in the GP group) and the covariates, including patient medical training background, characteristics of patient, prescriber, and medical settings, and market competition. A generalized estimating equation method was used to control the dependency of longitudinal data. Results: A total of 46850 diabetic patients were prescribed with 2703149 OHA prescriptions during the study period. Compared with GP, MP had 1.37 times greater odds of being prescribed with brand-name instead of generic OHA, among whom pharmacists and physicians had the highest odds ratios of 2.78 (95%CI, 1.05-7.36) and 1.68 (95%CI, 0.99-2.85), respectively. Patients' diabetes severity, prescribers' level of experience, medical settings that were publicly owned, had a higher accreditation level, and were located in a higher urbanized area, lower market competition, and earlier dates of prescription were positively associated with brand-name prescription. Among all medical sub-specialties, cardiologists were more likely to prescribe brand-name OHA. Conclusions: This study is the first to demonstrate how a patients' medical training background, in addition to the characteristics of patients, prescribers, and medical settings, and market competition might influence physicians' prescribing choice of brand-name or generic OHA.

KW - Brand name or generic

KW - Database analysis

KW - Pharmacoepidemiology

KW - Prescribing behavior

UR - http://www.scopus.com/inward/record.url?scp=84880037592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880037592&partnerID=8YFLogxK

U2 - 10.1002/pds.3445

DO - 10.1002/pds.3445

M3 - Article

C2 - 23625864

AN - SCOPUS:84880037592

VL - 22

SP - 752

EP - 759

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 7

ER -